Moreover, in poorly immunogenic and “non-inflamed” EGFR-driven lung cancer, oral administration of a specific glutamine antagonist against cancer cells, JHU083, facilitated the enrichment of CD8+ T cells [323, 324]. Here, CD8A is linked to lung cancer.